Paroxysmal Nocturnal Hemoglobinuria from Bench to Bedside

Jeffrey Pu, Robert A. Brodsky

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disease that presents with protean manifestations. Clinical and laboratory investigation over the past 25 years has uncovered most of the basic science underpinnings of PNH and has led to the development of a highly effective targeted therapy. PNH originates from a multipotent hematopoietic stem cell (HSC) that acquires a somatic mutation in a gene called phosphatidylinositol glycan anchor biosynthesis, class A (PIG-A). The PIG-A gene is required for the first step in glycosylphosphatidylinositol (GPI) anchor biosynthesis. Failure to synthesize GPI anchors leads to an absence of all proteins that utilize GPI to attach to the plasma membrane. Two GPI-anchor proteins, CD55 and CD59, are complement regulatory proteins; their absence on the surface of PNH cells leads to complement-mediated hemolysis. The release of free hemoglobin leads to scavenging of nitric oxide and contributes to many clinical manifestations, including esophageal spasm, fatigue, and possibly thrombosis. Aerolysin is a pore-forming toxin that binds GPI-anchored proteins and kills normal cells, but not PNH cells. A fluorescinated aerolysin variant (FLAER) binds GPI-anchor and serves as a novel reagent diagnosing PNH. Eculizumab, a humanized monoclonal antibody against C5, is the first effective drug therapy for PNH.

Original languageEnglish (US)
Pages (from-to)219-224
Number of pages6
JournalClinical and Translational Science
Volume4
Issue number3
DOIs
StatePublished - Jun 1 2011

Fingerprint

Paroxysmal Hemoglobinuria
Glycosylphosphatidylinositols
Biosynthesis
Proteins
Diffuse Esophageal Spasm
Genes
Multipotent Stem Cells
Drug therapy
Antibodies, Monoclonal, Humanized
Hematologic Diseases
Scavenging
Cell membranes
Rare Diseases
Hematopoietic Stem Cells
Hemolysis
Stem cells
Anchors
Fatigue
Complement System Proteins
Nitric Oxide

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pu, Jeffrey ; Brodsky, Robert A. / Paroxysmal Nocturnal Hemoglobinuria from Bench to Bedside. In: Clinical and Translational Science. 2011 ; Vol. 4, No. 3. pp. 219-224.
@article{3dbd611a6ebd4d9894f98e3856bbaf0c,
title = "Paroxysmal Nocturnal Hemoglobinuria from Bench to Bedside",
abstract = "Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disease that presents with protean manifestations. Clinical and laboratory investigation over the past 25 years has uncovered most of the basic science underpinnings of PNH and has led to the development of a highly effective targeted therapy. PNH originates from a multipotent hematopoietic stem cell (HSC) that acquires a somatic mutation in a gene called phosphatidylinositol glycan anchor biosynthesis, class A (PIG-A). The PIG-A gene is required for the first step in glycosylphosphatidylinositol (GPI) anchor biosynthesis. Failure to synthesize GPI anchors leads to an absence of all proteins that utilize GPI to attach to the plasma membrane. Two GPI-anchor proteins, CD55 and CD59, are complement regulatory proteins; their absence on the surface of PNH cells leads to complement-mediated hemolysis. The release of free hemoglobin leads to scavenging of nitric oxide and contributes to many clinical manifestations, including esophageal spasm, fatigue, and possibly thrombosis. Aerolysin is a pore-forming toxin that binds GPI-anchored proteins and kills normal cells, but not PNH cells. A fluorescinated aerolysin variant (FLAER) binds GPI-anchor and serves as a novel reagent diagnosing PNH. Eculizumab, a humanized monoclonal antibody against C5, is the first effective drug therapy for PNH.",
author = "Jeffrey Pu and Brodsky, {Robert A.}",
year = "2011",
month = "6",
day = "1",
doi = "10.1111/j.1752-8062.2011.00262.x",
language = "English (US)",
volume = "4",
pages = "219--224",
journal = "Clinical and Translational Science",
issn = "1752-8054",
publisher = "Wiley-Blackwell",
number = "3",

}

Paroxysmal Nocturnal Hemoglobinuria from Bench to Bedside. / Pu, Jeffrey; Brodsky, Robert A.

In: Clinical and Translational Science, Vol. 4, No. 3, 01.06.2011, p. 219-224.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Paroxysmal Nocturnal Hemoglobinuria from Bench to Bedside

AU - Pu, Jeffrey

AU - Brodsky, Robert A.

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disease that presents with protean manifestations. Clinical and laboratory investigation over the past 25 years has uncovered most of the basic science underpinnings of PNH and has led to the development of a highly effective targeted therapy. PNH originates from a multipotent hematopoietic stem cell (HSC) that acquires a somatic mutation in a gene called phosphatidylinositol glycan anchor biosynthesis, class A (PIG-A). The PIG-A gene is required for the first step in glycosylphosphatidylinositol (GPI) anchor biosynthesis. Failure to synthesize GPI anchors leads to an absence of all proteins that utilize GPI to attach to the plasma membrane. Two GPI-anchor proteins, CD55 and CD59, are complement regulatory proteins; their absence on the surface of PNH cells leads to complement-mediated hemolysis. The release of free hemoglobin leads to scavenging of nitric oxide and contributes to many clinical manifestations, including esophageal spasm, fatigue, and possibly thrombosis. Aerolysin is a pore-forming toxin that binds GPI-anchored proteins and kills normal cells, but not PNH cells. A fluorescinated aerolysin variant (FLAER) binds GPI-anchor and serves as a novel reagent diagnosing PNH. Eculizumab, a humanized monoclonal antibody against C5, is the first effective drug therapy for PNH.

AB - Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disease that presents with protean manifestations. Clinical and laboratory investigation over the past 25 years has uncovered most of the basic science underpinnings of PNH and has led to the development of a highly effective targeted therapy. PNH originates from a multipotent hematopoietic stem cell (HSC) that acquires a somatic mutation in a gene called phosphatidylinositol glycan anchor biosynthesis, class A (PIG-A). The PIG-A gene is required for the first step in glycosylphosphatidylinositol (GPI) anchor biosynthesis. Failure to synthesize GPI anchors leads to an absence of all proteins that utilize GPI to attach to the plasma membrane. Two GPI-anchor proteins, CD55 and CD59, are complement regulatory proteins; their absence on the surface of PNH cells leads to complement-mediated hemolysis. The release of free hemoglobin leads to scavenging of nitric oxide and contributes to many clinical manifestations, including esophageal spasm, fatigue, and possibly thrombosis. Aerolysin is a pore-forming toxin that binds GPI-anchored proteins and kills normal cells, but not PNH cells. A fluorescinated aerolysin variant (FLAER) binds GPI-anchor and serves as a novel reagent diagnosing PNH. Eculizumab, a humanized monoclonal antibody against C5, is the first effective drug therapy for PNH.

UR - http://www.scopus.com/inward/record.url?scp=79959689096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959689096&partnerID=8YFLogxK

U2 - 10.1111/j.1752-8062.2011.00262.x

DO - 10.1111/j.1752-8062.2011.00262.x

M3 - Article

C2 - 21707954

AN - SCOPUS:79959689096

VL - 4

SP - 219

EP - 224

JO - Clinical and Translational Science

JF - Clinical and Translational Science

SN - 1752-8054

IS - 3

ER -